This segment is led by a duopoly: Novo Nordisk's semaglutide (Ozempic for diabetes, Wegovy for obesity) and Eli Lilly's tirzepatide (Mounjaro for T2D, Zepbound for obesity and sleep apnea) together commanded 57.4% of the overall peptide therapy market in 2026 an extraordinary concentration in a USD 84.2 billion market
The Glucagon Paradox: Why Activating a Blood Sugar Hormone Can Improve Metabolic Health 3 weeks ago Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity, Obesity, Therapies, Type 2 Diabetes, Type 2 Diabetes 997 views For decades, glucagon has been viewed as insulins opposite
Vitamin B12, Fact Sheet for Health Professionals, National Institutes of Health, Office of Dietary Supplements Common questions about hydroxocobalamin, NHS (National Health Service), Hunt A, Harrington D, Robinson S
Mood Balance: Supports emotional stability and positive outlook